Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 11Multiple Myeloma 10Fallopian Tube Neoplasms 7Carcinoma, Ovarian Epithelial 6Breast Neoplasms 6Neoplasms, Plasma Cell 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Lymphoma 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Participation 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Osteosarcoma 1Neurofibrosarcoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

toripalimab 2Trabectedin 2Doxorubicin 2Docetaxel 2Biopsy 2temsirolimus 1silmitasertib 1selinexor 1pazopanib 1palbociclib 1nilotinib 1mirdametinib 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1eribulin 1cemiplimab 1avelumab 1abemaciclib 1Vincristine 1Temozolomide 1Specimen Handling 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Proton Therapy 1Nelfinavir 1Irinotecan 1Immunoenzyme Techniques 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma × liposomal doxorubicin × Clear all
NCT00949325 2019-03-11

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
24 enrolled 14 charts
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡